

NC Medicaid and NC Health Choice Pharmacy Prior Approval Request for Antinarcolepsy: Sunosi

Beneficiary Information 1. Beneficiary Last Name: _____ 4. Beneficiary Date of Birth: _______ 5. Beneficiary Gender: 3. Beneficiary ID #: Prescriber Information 6. Prescribing Provider NPI #: 7. Requester Contact Information - Name: ______ Phone #: _____ Ext. Drug Information 9. Strength: ______ 10. Quantity Per 30 Days: ____ 8. Drug Name: 11. Length of Therapy (in days): Initial Authorization: □ up to 30 Days □ 60 Days □ 90 Days Reauthorization: ☐ up to 30 Days ☐ 60 Days ☐ 90 Days ☐ 120 Days ☐ 180 Days Clinical Information 1. Is the beneficiary 18 years of age or older? \square Yes \square No 2. Does the beneficiary have an adequate documented trial and failure of, or contraindication to, Provigil or Nuvigil? 3. Does the beneficiary have a diagnosis of obstructive sleep apnea (OSA)? \square Yes \square No 4. Does the beneficiary have a diagnosis of narcolepsy? \square Yes \square No 5. Does the beneficiary have end stage renal disease (estimated glomerular filtration rate [eGFR] < 15ml/min/1.73m2)? ☐ Yes ☐ No 6. Has the beneficiary's blood pressure been assessed and hypertension controlled (≤ 140/90 mmHg) prior to initiating treatment? \(\subseteq \text{Yes} \(\subseteq \text{No} \) 7. Has the beneficiary received an MAO inhibitor within the previous 14 days? \square Yes \square No 8. Is the beneficiary receiving concomitant noradrenergic medications? \square **Yes** \square **No** 9.. If using to treat OSA, does the provider attest that the beneficiary is compliant with and will continue using positive airway pressure (PAP)? ☐ Yes ☐ No 10. If using to treat OSA, has the prescriber excluded any other identifiable causes for beneficiary's sleepiness (e.g. noncompliance with PAP, improperly fitted AP mask, insufficient sleep, poor sleep hygiene, depression, and/or other sleep disorders)? ☐ **Yes** ☐ **No** For continuation of therapy, please answer questions 1-12

11. Has the beneficiary developed increased blood pressure or heart rate that was not controlled by dose reduction of solriamfetol (Sunosi) or medical intervention? ☐ Yes ☐ No

12. Has the beneficiary reported a documented reduction in excessive daytime sleepiness from pre-treatment baseline as measured by a validated scale (e.g., Epworth Sleepiness Scale, Stanford Sleepiness Scale, Karolinska Sleepiness Scale, Cleveland Adolescent Sleepiness Questionnaire, or a Visual Analog Scale)?

Yes
No

Signature of Prescriber: ______ Date: ______ Date: ______

Pharmacy PA Call Center: (866) 246-8505

03/17/2021